◼ Archived
Business
Shionogi to Acquire IntraBio for $2 Billion
Japanese pharmaceutical company Shionogi has agreed to acquire Texas-based rare disease biotech IntraBio in a deal valued at $2 billion.
Intrabio
1 trends tracked about this subject — the full history, oldest to newest below.